

**WE CLAIM:**

- 1 1. An amorphous form of moxifloxacin hydrochloride.
- 1 2. The amorphous form of moxifloxacin hydrochloride of claim 1, wherein the  
2 moxifloxacin hydrochloride has the infrared spectrum of Figure 1.
- 1 3. The amorphous form of moxifloxacin hydrochloride of claim 1, wherein the  
2 moxifloxacin hydrochloride has the X-ray diffraction pattern of Figure 2.
- 1 4. A pharmaceutical composition comprising:  
2 a therapeutically effective amount of an amorphous form of moxifloxacin  
3 hydrochloride; and one or more pharmaceutically acceptable carriers, excipients or  
4 diluents.
- 5 5. The pharmaceutical composition of claim 1, wherein the moxifloxacin  
6 hydrochloride has the infrared spectrum of Figure 1.
- 1 6. The pharmaceutical composition of claim 1, wherein the moxifloxacin  
2 hydrochloride has the X-ray diffraction pattern of Figure 2.
- 1 7. A process for the preparation of the amorphous form of moxifloxacin  
2 hydrochloride, the process comprising:  
3 preparing a solution of moxifloxacin hydrochloride in one or more solvents; and  
4 recovering the moxifloxacin hydrochloride in the amorphous form from the  
5 solution thereof by the removal of the solvent.
- 1 8. The process of claim 7, wherein the solvent comprises one or more of lower  
2 alkanol, ketone, chlorinated solvent, or mixtures thereof.
- 1 9. The process of claim 8, wherein the lower alkanol comprises one or more of  
2 primary, secondary and tertiary alcohol having from one to six carbon atoms.
- 1 10. The process of claim 8, wherein the lower alkanol comprises one or more of  
2 methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol,  
3 and t-butanol.

- 1 11. The process of claim 8, wherein the lower alkanol comprises one or more of  
2 methanol, ethanol, and denatured spirit.
- 1 12. The process of claim 8, wherein the ketone comprises one or more of acetone,  
2 2-butanone, and 4-methylpentan-2-one.
- 3 13. The process of claim 8, wherein the chlorinated solvent comprises one or more of  
4 chloroform, dichloromethane, and dichloroethane.
- 1 14. The process of claim 7, wherein removing the solvent comprises one or more of  
2 distillation, distillation under vacuum, evaporation, spray drying, freeze drying,  
3 filtration, decantation, and centrifugation.
- 1 15. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous  
2 form is recovered from the solution by spray drying.
- 1 16. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous  
2 form is recovered from the solution by freeze-drying.
- 3 17. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous  
4 form is recovered from the solution by filtration.
- 1 18. The process of claim 7, further comprising additional drying of the product  
2 obtained.
- 1 19. The process of claim 7, further comprising forming the product obtained into a  
2 finished dosage form.
- 1 20. The process of claim 7, wherein the moxifloxacin hydrochloride has the infrared  
2 spectrum of Figure 1.
- 1 21. The process of claim 7, wherein the moxifloxacin hydrochloride has the X-ray  
2 diffraction pattern of Figure 2.